Elsevier

Contraception

Volume 63, Issue 6, June 2001, Pages 297-302
Contraception

Original research article
Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials

https://doi.org/10.1016/S0010-7824(01)00208-6Get rights and content

Abstract

Changes in body weight and the incidence of estrogen-related side effects with low-dose oral contraceptives (OCs) containing 20 μg ethinyl estradiol (EE) have not been demonstrated in placebo-controlled trials. Two placebo-controlled, randomized trials demonstrated the efficacy of a low-dose OC for the treatment of acne in healthy females (n = 704; ≥14 years old) with regular menstrual cycles and moderate facial acne. Patients were randomized to receive 20 μg EE/100 μg levonorgestrel (LNG) or placebo for six cycles. Body weight was measured at baseline and during Cycles 1, 3, and 6. The occurrence of adverse events was recorded at each visit. Mean changes in weight from baseline were similar with 20 μg EE/100 μg LNG [0.72 kg ± 2.64 (SD; n = 349)] and placebo [0.56 kg ± 2.64 (SD; n = 355; p > 0.05)] for the last measured weight of each patient. Rates of headache, nausea, weight gain, and breast pain, side effects commonly attributed to OCs, were also similar between groups (p > 0.05). No serious, unexpected, drug-related adverse events occurred during the study. The low-dose OC containing 20 μg EE/100 μg LNG is safe, well tolerated, and does not cause weight gain.

Introduction

Historically, oral contraceptives (OCs) have been associated with estrogen-related side effects, including nausea, headache, and breast tenderness [1]. One goal of lowering the hormonal content of OCs, besides minimizing the rare occurrence of cardiovascular events, is to reduce the incidence of these side effects. The only trial so far comparing the incidence of side effects with OCs containing 20 versus 35 μg ethinyl estradiol (EE) showed a lower incidence of nausea, breast tenderness, and bloating with the 20 μg pills [2].

According to a recent survey, more than half of US women believe OCs cause weight gain [3]. However, evidence in favor of this common misconception has not been demonstrated in placebo-controlled trials. An early placebo-controlled trial that reported measured weight changes with OCs containing high doses of hormones found similar measured weight changes in the OC and placebo groups [4]. Additionally, two placebo-controlled trials with a triphasic OC containing 35 μg EE and norgestimate found a similar incidence of weight gain recorded as an adverse event, although measured weight gain was not reported [5]. Placebo-controlled trials evaluating the effect of low-dose OCs containing 20 μg EE on measured weight gain have not been reported.

In studies reporting the contraceptive efficacy of 20 μg OCs, minimal weight gain [6], [7] and a low incidence of discontinuation because of weight gain [8] were demonstrated. Other trials, lacking placebo controls, that examined the effects of OCs on weight found little or no effect [9], [10], [11], [12], [13], [14], [15], [16], [17], [18]. In the absence of a placebo control, any effect of an OC on weight change observed in efficacy or observational trials cannot be attributed to the OC. A placebo can be used to control for normal weight change over time, among other variables.

To generate more conclusive results on the effects of a 20 μg OC on weight and the rates of common OC-related side effects, data were pooled and analyzed from two 6-cycle, randomized, placebo-controlled, double-blind trials of a low-dose OC containing 20 μg EE and 100 μg levonorgestrel (LNG) that demonstrated efficacy for the treatment of moderate acne. Changes in measured weight and the incidence of adverse events (AEs) were compared between the OC and placebo groups.

Section snippets

Patients

Healthy women at least 14 years of age with regular menstrual cycles and moderate facial acne were eligible to participate. Participants were required to have normal cervical cytology in the last 6 months or, if an abnormal Papanicolaou smear, not worse than low-grade squamous intraepithelial lesion and be under the evaluation or treatment of a physician. Participants must have had a negative pregnancy test before entering the study and have agreed to use a nonhormonal method of contraception

Disposition

Of the 721 women enrolled in the study, a similar number from each group withdrew (EE/LNG 124, placebo 125) and completed (EE/LNG 235, placebo 237) the study. Six hundred eighty-four patients (EE/LNG 337, placebo 347) took at least one dose of study medication. Body weight, blood pressure, and AEs were analyzed in a total of 704 (EE/LNG 349, placebo 355) women, which included 20 women (EE/LNG 12, placebo 8) for whom information on taking study medication was not available.

Subject demographic and baseline characteristics

The demographic and

Discussion

In the current pooled analysis of two placebo-controlled, randomized, double-blind, multicenter clinical trials, a low-dose OC containing 20 μg EE and 100 μg LNG did not cause weight gain and was safe and well tolerated. The EE/LNG and placebo groups displayed comparable changes in weight from baseline over six cycles of treatment. Estrogen-related side effects [1], such as headache, nausea, breast pain, and weight gain, occurred with a similar incidence between groups, and low, comparable

Acknowledgements

We thank the additional investigators who participated in the study: David F. Archer, MD; Alan Cooper, MD; Frank Dunlap, MD; Douglass Forsha, MD; Maria Hordinsky, MD; Michael Jarratt, MD; Joseph Jorizzo, MD; Sewon Kang, MD; Steven Kempers, MD; Nellie Konnikov, MD; André Lemay, MD, PhD; James Leyden, MD; Mark Ling, MD, PhD; Anne Lucky, MD; Alan Menter, MD; Daniel Piacquadio, MD; Walter Powell, MD; Janet Roberts, MD; David Rodriguez, MD; Hans Sander, MD; Ronald Savin, MD; Alan Shalita, MD; Daniel

References (26)

Cited by (92)

  • Diet and exercise in the management of PCOS: Starting from the basics

    2022, Polycystic Ovary Syndrome: Challenging Issues in the Modern Era of Individualized Medicine
  • Gynecologic and Obstetric Consequences of Obesity in Adolescent Girls

    2017, Journal of Pediatric and Adolescent Gynecology
  • The combined oral contraceptive pill- recent developments, risks and benefits

    2014, Best Practice and Research: Clinical Obstetrics and Gynaecology
  • Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: A systematic review

    2013, Contraception
    Citation Excerpt :

    Summary measures of association were not computed due to heterogeneity among studies with respect to study design, subject characteristics and outcomes. Our search strategy identified 1901 articles, of which 5 met our study selection criteria (Table 1) [4–8]. One was a randomized controlled trial (RCT) [8], one was cohort analysis from a partially RCT [6], and three were prospective cohort studies [4,5,7].

View all citing articles on Scopus

The research was supported by Wyeth-Ayerst Laboratories.

1

Current Address: Dalhousie University, Halifax, Nova Scotia.

View full text